A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (NCT07277231)

🧪 Interventions in This Study

• Sonrotoclax (DRUG)
• Zanubrutinib (DRUG)
• Acalabrutinib (DRUG)
• Venetoclax (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (105 Sites)

Showing the first 25 of 105 sites.

• City of Hope National Medical Center — Duarte, California
• Chao Family Comprehensive Cancer Center — Orange, California
• Stanford Cancer Institute — Palo Alto, California
• Rocky Mountain Cancer Centers (Williams) Usor — Aurora, Colorado
• Mount Sinai Medical Center Braman Comprehensive Cancer Center — Miami, Florida
• Northwestern University — Chicago, Illinois
• Midwestern Regional Medical Center — Zion, Illinois
• Ochsner Clinic Foundation — New Orleans, Louisiana
• University of Nebraska Medical Center — Omaha, Nebraska
• Upmc Hillman Cancer Center(Univ of Pittsburgh) — Pittsburgh, Pennsylvania
• Texas Oncology Tyler — Tyler, Texas
• Fred Hutchinson Cancer Research Center — Seattle, Washington
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Blacktown Cancer and Haematology Centre — Blacktown, New South Wales
• Concord Repatriation General Hospital — Concord, New South Wales
• Genesiscare North Shore — St Leonards, New South Wales
• Princess Alexandra Hospital — Woolloongabba, Queensland
• Monash Health — Clayton, Victoria
• Austin Health — Heidelberg, Victoria
• Cabrini Hospital Malvern — Malvern, Victoria
• The Alfred Hospital — Melbourne, Victoria
• Instituto Dor de Pesquisa E Ensino Distrito Federal — Brasília,
• Centro Gaucho Integrado de Oncologia Hospital Mae de Deus — Porto Alegre,
• Ensino E Terapia de Inovacao Clinica Amo Etica — Salvador,
• Instituto Dor de Pesquisa E Ensino Sao Paulo — São Paulo,

📞 Contact the Study Coordinator

Phone: (877) 828-5568

Email: clinicaltrials@beonemed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Lymphocytic Leukemia

• Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
• Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
• A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
• Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona
• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona

Explore by condition: All Chronic Lymphocytic Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.